Search Results
Your search for ,maY matches 16983 pages
Showing 2301 - 2350Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Hematologic Oncology 2023 Almanac
The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...
T-Cell Tolerant Fraction May Predict Immune-Related Adverse Events Among Patients Receiving Immunotherapy
Researchers have identified a novel parameter of T cells that may help oncologists anticipate which patients are most likely to develop immunotherapy toxicity. The findings, published by Ostmeyer in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of ...
Vigorous Intermittent Lifestyle Physical Activity and Cancer Incidence Among Nonexercising Adults
In an analysis from the UK Biobank Accelerometry Study reported in JAMA Oncology, Stamatakis et al found that bouts of vigorous intermittent lifestyle physical activity were associated with reduced risk of cancer among nonexercising adults. Vigorous intermittent lifestyle physical activity refers...
Are Immune Checkpoint Inhibitors Efficacious Among Patients With Penile Squamous Cell Carcinoma?
Penile squamous cell carcinoma is a rare type of penile cancer with limited treatment options. An international study has found that the use of immune checkpoint inhibitors may offer clinical benefits for some patients with advanced penile squamous cell carcinoma. These findings were published by...
AI-Driven Muscle Mass Assessment May Aid in Detecting Sarcopenia in Patients With Head and Neck Cancer
Researchers have found a way to use artificial intelligence (AI) to diagnose sarcopenia in patients with head and neck cancer. The tool may be used to improve treatment and supportive care for patients, according to a report published by Ye et al in JAMA Network Open. “Sarcopenia is an indicator...
Risk of Death, Cancer, and Autoimmune Disease Among Patients Undergoing Thymectomy
In a single-institution study reported in The New England Journal of Medicine, Kooshesh et al found that adults who had undergone thymectomy may be at an increased risk of death; cancer; and, in certain cases, autoimmune disease. As stated by the investigators: “The function of the thymus in human...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
CAR T-Cell Therapies: Trends and Indications
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
Alcohol Consumption and Risk of Breast Cancer Recurrence
A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...
Does Daily Consumption of Sugar-Sweetened Beverages Increase the Risk of Liver Disease Among Postmenopausal Women?
Approximately 65% of adults in the United States consume sugar-sweetened beverages daily. Researchers led a study examining the associations among intake of sugar-sweetened or artificially sweetened beverages and the incidence of liver cancer and chronic liver disease mortality in a large cohort of ...
Elevated MRI Enhancement May Indicate Increased Risk of Cancer in Patients With Very Dense Breasts
A machine-learning model found that background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be an indicator of breast cancer risk in patients with extremely dense breasts, according to a study published by Wang et al in Radiology. Patients with extremely dense...
Cancer Care Providers Applaud New Federal Rule Regulating Short-Term Limited Duration Plans
On July 7, 2023, the Department of Health and Human Services (HHS), Department of Labor, and the Treasury Department issued a proposed rule regulating the availability of short-term limited duration insurance plans. The rule would restrict the availability of these plans to no more than 4 months....
ASCO Awarded $11 Million to Study Oral Drug Dosing Strategies in Older Adults With Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
ASCO has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this...
Expert Point of View: Daniel G. Stover, MD
Formal discussant Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, said the SONIA and PALMIRA trials raised several questions. Can CDK4/6 inhibitors be personalized and differentiated? Can patients delay treatment with these agents? Should all patients receive a...
Should CDK4/6 Inhibitors Be a First-Line Option for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer?
Two studies presented at the 2023 ASCO Annual Meeting challenge the use of CDK4/6 inhibitors as part of upfront treatment of advanced hormone receptor–positive, HER2-negative breast cancer. The first, the SONIA trial, found that first-line treatment with CDK4/6 inhibitors led to greater toxicity...
On the Art of Organizing Best of ASCO Meetings
Preparing and running a medical conference is usually a complex but rewarding mission. It is a demanding job that is typically done voluntarily by physicians and educators who are dedicated to professional and community service; advancement of research and education; as well as the dissemination of ...
How Multidisciplinary Specialties Are Coming Together to Improve the Quality of Life of Cancer Survivors
As we detailed in our Special Report “Surviving, but Not Always Thriving, After Cancer,” in the May 25, 2023, issue of The ASCO Post, the combination of advances in more effective therapies to treat cancer, gains in early detection, and sharp declines in tobacco use have led to a staggering 33%...
Expert Point of View: Barbara Pistilli, MD
The invited discussant of the study by Bar et al, Barbara Pistilli, MD, Head of the Breast Cancer Unit at Gustave Roussy Cancer Center, Villejuif, France, noted that third-generation antibody-drug conjugates, such as fam-trastuzumab deruxtecan-nxki (T-DXd), are showing activity across a wide range ...
HER2-Low Status Is ‘Dynamic’ for Patients With Triple-Negative Breast Cancer
The probability of obtaining a HER2-low test result increases with the number of biopsies performed, according to a study of more than 500 biopsy samples in patients with triple-negative breast cancer. For patients originally labeled as having no HER2 expression (HER2 0), each successive biopsy...
Fine Particulate Matter Exposure May Increase Risk of Primary Cancers Other Than Lung Cancer
Chronic exposure to fine particulate air pollutants (PM2.5, particulate matter 2.5 µm in diameter) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, according to a study published by Yaguang et al in Environmental Epidemiology. In a cohort study of millions of Medicare...
Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns
New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...
Study Shows Substantial Racial and Ethnic Disparities Among Survivors of Second Primary Cancers in the United States
In a new study published by Hyuna Sung, PhD, and colleagues in JAMA Network Open, non-Hispanic Black individuals diagnosed with a second primary cancer experienced 21% higher cancer-related death rates and 41% higher cardiovascular-related death rates compared with non-Hispanic White individuals;...
Translating Consent Documents: Potential Barrier for Including Underrepresented Groups in Clinical Trials
Cancer research centers conducting clinical trials could potentially enroll more patients from underrepresented racial and ethnic groups by placing a greater emphasis on relieving investigators of the costs of translating consent documents into languages other than English, according to a study...
Analysis Challenges Theory That Depression and Anxiety May Increase Cancer Risk
Experts have suspected that depression and anxiety may increase cancer risk by affecting a person’s health-related behaviors or by having biological effects on the body that support cancer development. Some research has supported an association among depression, anxiety, and cancer incidence,...
How Does BMI Affect Cardiac Health for Patients With Breast Cancer Receiving Chemotherapy?
A study covering the northeast region of Colombia found nearly 12% of patients with a high body mass index (BMI) being treated for breast cancer at a regional center experienced cardiotoxicity during chemotherapy. The study will be presented at the upcoming American College of Cardiology Latin...
For Advanced Nasopharyngeal Cancer, Adjuvant Gemcitabine Plus Cisplatin Favored Over Fluorouracil Plus Cisplatin, Study Reports
In patients with N2 and N3 nasopharyngeal carcinoma, adjuvant treatment with concurrent gemcitabine and cisplatin significantly improved progression-free survival, with acceptable toxicity, over fluorouracil plus cisplatin, according to a phase III trial reported from Sun Yat-sen University Cancer...
Three Studies From ASCO 2023 Focus on Metastatic Castration-Resistant Prostate Cancer
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
Wildfire Exposure and Survival Outcomes After Surgery for NSCLC
Investigators have found that exposure to wildfires within 1 year of surgery may significantly lower the chance of survival in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Zhang et al in JAMA Oncology. Background Lung cancer is the second most common...
Comparison of Outcomes of Surgical vs Nonsurgical Approaches in Patients With Malignant Bowel Obstructions
Researchers have compared the efficacy of surgical and nonsurgical interventions for patients with malignant bowel obstructions, according to a recent study published by Krouse et al in The Lancet Gastroenterology & Hepatology. The new findings may help to inform clinical decision-making in the ...
Early-Stage Cancer Diagnoses in the United States May Have Decreased During the First Year of the COVID-19 Pandemic
Investigators have found that monthly U.S. adult cancer diagnoses decreased by 50% early in April 2020 and that the largest decreases were observed for stage I tumors, resulting in a higher proportion of late-stage cancer diagnoses, according to a recent study published by Han et al in The Lancet...
ACP Issues Updated Clinical Guidelines for Screening Asymptomatic, Average-Risk Adults for Colorectal Cancer
The American College of Physicians (ACP) suggested screening asymptomatic, average-risk adults for colorectal cancer at age 50 years, according to updated clinical guidelines published by Qaseem et al in the Annals of Internal Medicine. New ACP Clinical Guidelines Colorectal cancer has the fourth...
Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors
About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent study published by Han et al in PLOS ONE. Background While depression, anxiety, and fatigue are...
Researchers Characterize Adverse Immune Events in Patients With Cancer Who Experience Immune Checkpoint Inhibitor–Associated Arthritis
Researchers may have uncovered the immune adverse events and the specific type of CD8 T cells that characterize inflammatory arthritis induced by immune checkpoint inhibitors, according to a recent study published by Wang et al in Science Immunology. Immune checkpoint inhibitors used to treat...
Expert Point of View: Joshua Zeidner, MD
Joshua Zeidner, MD, Associate Professor of Medicine, Chief of Leukemia Research, and Associate Chief of Hematology Research at the University of North Carolina Lineberger Comprehensive Cancer Center, emphasized the high risk of relapse, even after allogeneic stem cell transplantation, for patients ...
Gilteritinib Maintenance Therapy After Transplantation in Patients With FLT3-ITD AML Who Have Measurable Residual Disease
A new therapeutic option is under study for use in a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to a presentation during the European Hematology Association (EHA) 2023 Hybrid Congress.1 Exploratory results of the phase III MORPHO trial showed a benefit to the ...
Researchers May Have Uncovered Two New Subtypes of HPV-Positive Head and Neck Squamous Cell Carcinomas
Human papillomavirus (HPV)–positive head and neck squamous cell carcinomas can be divided into two distinct subtypes that may help determine how well patients will respond to therapy, according to a novel study published by Schrank et al in PNAS. The findings also identified a new mechanism of HPV...
Can an AI-Based Tool Accurately Detect Precancerous Cervical Lesions?
Researchers in Japan have developed an artificial intelligence (AI)-based diagnostic tool for colposcopy examinations that may accurately identify cervical intraepithelial neoplasia (CIN) and subsequently suggest appropriate biopsy sites. The research will be presented by Ueda et al at the 2023...
Exercise May Reduce Sexual Dysfunction Caused by Prostate Cancer Treatment
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer, according to a new study conducted in Australia. The research was presented by Galvao et al at the 2023 ASCO Breakthrough meeting (Abstract 71) in Yokohama, Japan. “Sexual dysfunction is a ...
Molecular Classification and Response to Radiotherapy in Early-Stage Endometrioid Endometrial Cancer
In a Dutch analysis reported in the Journal of Clinical Oncology, Horeweg et al found that molecular classification predicted response to radiotherapy in patients with early-stage endometrioid endometrial cancer. As stated by the investigators, “The molecular classification of endometrial cancer...
Expert Point of View: Anand Ashwin Patel, MD
As presented at the 2023 ASCO Annual Meeting, the phase III IMerge trial of imetelstat1 and the phase III COMMANDS trial of luspatercept2 met their primary endpoints of transfusion independence. The findings suggest that lower-risk patients with transfusion-dependent, non-del(5q) myelodysplastic...
Short Bursts of Vigorous Daily Activity May Be Linked to Reduced Cancer Incidence
Investigators have found that just 4.5 minutes of vigorous activity per day could reduce the risk of some cancer types by up to 32%. The results of the recent study were published by Stamatakis et al in JAMA Oncology. Background Vigorous intermittent lifestyle physical activity describes very...
Patients in Lower-Income Communities May Be Less Likely to Receive CT Colonography Than Those in Higher-Income Communities
Patients who reside in lower-income communities may be less likely to undergo colorectal cancer screenings with computed tomography (CT) colonography than those who reside in higher-income communities, according to a new study published by Christensen et al in the American Journal of ...
Atezolizumab With or Without Radiotherapy in Advanced Penile Cancer
In the Dutch single-institution phase II PERICLES trial reported in the Journal of Clinical Oncology, de Vries et al found atezolizumab produced activity in patients with advanced squamous cell carcinoma of the penis. Study Details In the study, 32 patients enrolled at The Netherlands Cancer...
Reasons for Nonparticipation in a Colorectal Cancer Screening Trial Comparing Outcomes With Colonoscopy vs FIT
In an analysis reported in JAMA Network Open, Robertson et al found U.S. veterans most frequently cited a preference for stool testing as a reason for declining participation in the CONFIRM trial, which compared the effect on colorectal cancer mortality with annual colonoscopy vs annual fecal...
Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer
As a first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, the PD-L1 inhibitor durvalumab plus weekly carboplatin and paclitaxel provided clinically significant efficacy in the phase II FRAIL-IMMUNE (GORTEC 2018-03) trial.1 This regimen may prove to be an effective...
Skin Cancer Screenings and Melanoma Outcomes Among Racial and Ethnic Minority Patients
Increased skin cancer screenings may not reduce disparities in the survival rates of patients with melanoma who have darker skin tones, according to a recent study published by Smith et al in JAMA Dermatology. Background Although melanoma—the leading cause of skin cancer mortality—is most common...
Modeled Effects of Reducing the Recommended Screening Age for Colorectal Cancer in Canada
In a modeling study reported in JAMA Oncology, Kalyta et al found that reducing the starting age for colorectal cancer screening with the biennial fecal immunochemical test (FIT) in Canada would result in reduction in colorectal cancer burden at a “modest cost.” As stated by the investigators:...
The Role of U.S. Cancer Centers in Preparing Patients With Cancer for Climate Change Emergencies
Investigators have proposed that cancer centers may be uniquely positioned to protect communities and patients with cancer from climate-driven disasters by bolstering climate change–associated emergency preparedness, according to a recent study published by Espinel et al in the Journal of the...
